MX2020001873A - Agentes de union. - Google Patents
Agentes de union.Info
- Publication number
- MX2020001873A MX2020001873A MX2020001873A MX2020001873A MX2020001873A MX 2020001873 A MX2020001873 A MX 2020001873A MX 2020001873 A MX2020001873 A MX 2020001873A MX 2020001873 A MX2020001873 A MX 2020001873A MX 2020001873 A MX2020001873 A MX 2020001873A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding portions
- antibody molecules
- binding
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1713298.6A GB201713298D0 (en) | 2017-08-18 | 2017-08-18 | Binding agents |
| GBGB1802595.7A GB201802595D0 (en) | 2018-02-16 | 2018-02-16 | Binding agents |
| GBGB1808570.4A GB201808570D0 (en) | 2018-05-24 | 2018-05-24 | Binding agents |
| PCT/GB2018/052347 WO2019034895A1 (en) | 2017-08-18 | 2018-08-17 | LIAISON AGENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001873A true MX2020001873A (es) | 2020-10-22 |
Family
ID=63371721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001873A MX2020001873A (es) | 2017-08-18 | 2018-08-17 | Agentes de union. |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10683350B2 (enExample) |
| EP (2) | EP4435008A2 (enExample) |
| JP (4) | JP7256580B2 (enExample) |
| KR (1) | KR102781208B1 (enExample) |
| CN (1) | CN111212852A (enExample) |
| AU (2) | AU2018316742B2 (enExample) |
| BR (1) | BR112020003306A2 (enExample) |
| CA (1) | CA3072998A1 (enExample) |
| ES (1) | ES2983651T3 (enExample) |
| IL (1) | IL272643A (enExample) |
| MX (1) | MX2020001873A (enExample) |
| RU (1) | RU2020109544A (enExample) |
| SG (1) | SG11202001425TA (enExample) |
| WO (1) | WO2019034895A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019034895A1 (en) | 2017-08-18 | 2019-02-21 | Ultrahuman Four Limited | LIAISON AGENTS |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| EP3986935A4 (en) | 2019-06-19 | 2023-08-30 | Lepu Biopharma Co., Ltd. | Anti-cd47 antibodies and uses thereof |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2022003568A1 (en) | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| CN111733162A (zh) * | 2020-07-01 | 2020-10-02 | 江苏莱森生物科技研究院有限公司 | 一种经基因修饰的cd47蛋白及其单克隆抗体和应用 |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| WO2022140659A2 (en) | 2020-12-23 | 2022-06-30 | D-10 Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| CN112794903B (zh) * | 2021-04-14 | 2021-06-25 | 广州市雷德生物科技有限公司 | 一种特异性结合IFN-γ的抗体及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US20250129155A1 (en) * | 2021-06-30 | 2025-04-24 | Innobation Bio Co., Ltd. | Humanized antibody specific for cd47 and pharmaceutical composition for preventing or treating cd47-related diseases comprising the same |
| WO2023070353A1 (en) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anti-cd47 antibodies and methods of use thereof |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| IL314395A (en) | 2022-01-31 | 2024-09-01 | Centessa Pharmaceuticals Uk Ltd | Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023191117A1 (ko) * | 2022-03-28 | 2023-10-05 | (주)이노베이션바이오 | 친화도가 성숙된 cd47에 특이적인 인간화 항체 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａｓ調節化合物 |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4637749B2 (ja) * | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CN101231382B (zh) | 2008-02-26 | 2010-09-01 | 上海激光等离子体研究所 | 用于啁啾脉冲放大的光谱调制整形装置 |
| AU2011252851B2 (en) | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| ME03512B (me) * | 2012-02-06 | 2020-04-20 | Inhibrx Inc | Cd47 antitijela i postupci za njihovu upotrebu |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| MX2015007446A (es) * | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| WO2016081423A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| HK1245154A1 (zh) * | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| US10647756B2 (en) * | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| CN116425875A (zh) * | 2015-09-18 | 2023-07-14 | 安驰肿瘤公司 | 治疗性cd47抗体 |
| CA3011097C (en) * | 2016-01-11 | 2022-12-20 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| WO2019034895A1 (en) | 2017-08-18 | 2019-02-21 | Ultrahuman Four Limited | LIAISON AGENTS |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
-
2018
- 2018-08-17 WO PCT/GB2018/052347 patent/WO2019034895A1/en not_active Ceased
- 2018-08-17 CN CN201880066662.5A patent/CN111212852A/zh active Pending
- 2018-08-17 CA CA3072998A patent/CA3072998A1/en active Pending
- 2018-08-17 MX MX2020001873A patent/MX2020001873A/es unknown
- 2018-08-17 AU AU2018316742A patent/AU2018316742B2/en active Active
- 2018-08-17 KR KR1020207007972A patent/KR102781208B1/ko active Active
- 2018-08-17 BR BR112020003306-5A patent/BR112020003306A2/pt unknown
- 2018-08-17 JP JP2020530735A patent/JP7256580B2/ja active Active
- 2018-08-17 EP EP24179206.8A patent/EP4435008A2/en not_active Withdrawn
- 2018-08-17 SG SG11202001425TA patent/SG11202001425TA/en unknown
- 2018-08-17 RU RU2020109544A patent/RU2020109544A/ru unknown
- 2018-08-17 EP EP18759711.7A patent/EP3668897B1/en active Active
- 2018-08-17 ES ES18759711T patent/ES2983651T3/es active Active
-
2019
- 2019-08-19 US US16/543,884 patent/US10683350B2/en active Active
-
2020
- 2020-02-12 IL IL272643A patent/IL272643A/en unknown
- 2020-05-19 US US16/877,938 patent/US11370840B2/en active Active
-
2022
- 2022-06-24 US US17/849,101 patent/US20220332819A1/en not_active Abandoned
-
2023
- 2023-03-27 JP JP2023049983A patent/JP7564274B2/ja active Active
-
2024
- 2024-09-23 US US18/893,023 patent/US20250109202A1/en active Pending
- 2024-09-26 JP JP2024167571A patent/JP7825015B2/ja active Active
-
2025
- 2025-06-26 AU AU2025204808A patent/AU2025204808A1/en active Pending
-
2026
- 2026-02-20 JP JP2026026439A patent/JP2026094226A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10683350B2 (en) | 2020-06-16 |
| JP7564274B2 (ja) | 2024-10-08 |
| KR102781208B1 (ko) | 2025-03-17 |
| WO2019034895A1 (en) | 2019-02-21 |
| CA3072998A1 (en) | 2019-02-21 |
| US20220332819A1 (en) | 2022-10-20 |
| JP2023073339A (ja) | 2023-05-25 |
| AU2018316742B2 (en) | 2025-04-10 |
| ES2983651T3 (es) | 2024-10-24 |
| JP2026094226A (ja) | 2026-06-09 |
| SG11202001425TA (en) | 2020-03-30 |
| RU2020109544A (ru) | 2021-09-20 |
| KR20200038533A (ko) | 2020-04-13 |
| US11370840B2 (en) | 2022-06-28 |
| EP4435008A2 (en) | 2024-09-25 |
| IL272643A (en) | 2020-03-31 |
| JP7825015B2 (ja) | 2026-03-05 |
| US20250109202A1 (en) | 2025-04-03 |
| JP2020531048A (ja) | 2020-11-05 |
| BR112020003306A2 (pt) | 2020-08-25 |
| EP3668897A1 (en) | 2020-06-24 |
| US20190375840A1 (en) | 2019-12-12 |
| EP3668897B1 (en) | 2024-06-05 |
| US20200277375A1 (en) | 2020-09-03 |
| AU2018316742A1 (en) | 2020-03-19 |
| CN111212852A (zh) | 2020-05-29 |
| JP2025000787A (ja) | 2025-01-07 |
| JP7256580B2 (ja) | 2023-04-12 |
| AU2025204808A1 (en) | 2025-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| PH12019500545A1 (en) | Cd3 binding antibodies | |
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| MX2024005027A (es) | Anticuerpos de union a cd3. | |
| PH12018502623B1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| GB201005064D0 (en) | Biological products | |
| SG11201907321TA (en) | Anti-gprc5d antibody and molecule comprising the antibody | |
| PH12019502087A1 (en) | Anti-par2 antibodies and uses thereof | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| EP4374922A3 (en) | Anti-c5 antibodies and uses thereof | |
| MY181969A (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| WO2008140493A3 (en) | Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof | |
| EA201690310A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| DK2070948T3 (da) | Humant Anti-CD4-antistof med immunsuppressive egenskaber | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| NZ595235A (en) | Compositions and methods for increasing muscle growth | |
| AU2017206631A8 (en) | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies | |
| WO2009048537A3 (en) | Humanized antibody | |
| WO2011139974A3 (en) | Anti-pai-1 antibodies and methods of use thereof | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| MX381139B (es) | Anticuerpo anti-notch4 humano. | |
| SG10201801219VA (en) | Anti-HER2 Antibodies | |
| WO2011092593A3 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
| WO2018183182A8 (en) | Methods and compositions for reduction of immunogenicity |